CPhI: Reg­u­la­to­ry changes have led to a CMO boom in Chi­na, but can that con­tin­ue?

Con­tract man­u­fac­tur­ing for do­mes­tic com­pa­nies un­til re­cent­ly didn’t ex­ist in Chi­na, thanks to some reg­u­la­to­ry re­stric­tions that re­quired de­vel­op­ers to be in charge of their own man­u­fac­tur­ing process. Now, the young busi­ness mod­el is be­ing test­ed with high­er de­mand and ex­treme­ly fast growth as the CPhi In­for­ma­Mar­kets re­port ex­pects CMO ser­vices to con­tin­ue to ex­pand in the com­ing years.

In 2013, just four IND ap­pli­ca­tions were sub­mit­ted in Chi­na. That num­ber sky­rock­et­ed to 99 in 2020, fol­lowed by 94 al­ready in 2021. Chi­na is now the home of four PD-1 mAb ther­a­peu­tics, with an­oth­er five in the NDA process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER